百利天恒与BMS的创新药合作触发2.5亿美元里程碑付款

Core Insights - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (Baili Tianheng, 688506.SH) announced a significant milestone in its global II/III phase clinical trial IZABRIGHT-Breast01, triggering a $250 million near-term milestone payment under its collaboration agreement with Bristol-Myers Squibb (BMS) [1] - The payment will be received by Baili Tianheng's wholly-owned subsidiary SystImmune, Inc. for overseas drug development, marking the largest single milestone payment disclosed for a domestic innovative drug going abroad in the ADC asset category [1] - In December 2023, Baili Tianheng entered into an exclusive licensing and collaboration agreement with BMS for the independently developed iza-bren (BL-B01D1, EGFR×HER3 dual antibody ADC) project, which includes an $800 million upfront payment and two $250 million near-term payments [1] - The total potential transaction value could reach $8.4 billion, setting a record for the highest total price for a single drug licensing deal in the global ADC field [1]